Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 601 to 625 of 766

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Empagliflozin in combination therapy for treating type 2 diabetesTA336
Rifaximin for preventing episodes of overt hepatic encephalopathyTA337
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndromeTA335
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapyTA329
Sofosbuvir for treating chronic hepatitis CTA330
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentTA333
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)TA334
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanomaTA269
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA327
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapyTA323
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular blockTA324
Nalmefene for reducing alcohol consumption in people with alcohol dependenceTA325
Imatinib for the adjuvant treatment of gastrointestinal stromal tumoursTA326
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular blockTA88
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanomaTA321
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisTA320
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenTA316
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromesTA317
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanomaTA319
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failureTA314
Canagliflozin in combination therapy for treating type 2 diabetesTA315
Teriflunomide for treating relapsing–remitting multiple sclerosisTA303
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantationTA311
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitisTA308

Results per page

  1. 10
  2. 25
  3. 50
  4. All